Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor

AIDS. 2002 Sep 27;16(14):1959-61. doi: 10.1097/00002030-200209270-00014.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • Acquired Immunodeficiency Syndrome / virology*
  • Amino Acid Substitution
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • CD4-Positive T-Lymphocytes / immunology
  • Enfuvirtide
  • Evolution, Molecular
  • HIV Envelope Protein gp41 / adverse effects*
  • HIV Envelope Protein gp41 / genetics*
  • HIV Envelope Protein gp41 / therapeutic use
  • HIV-1 / genetics*
  • Humans
  • Peptide Fragments / adverse effects*
  • Peptide Fragments / therapeutic use
  • Receptors, CCR5
  • Sequence Analysis, DNA
  • Viremia / drug therapy
  • Viremia / virology

Substances

  • Anti-HIV Agents
  • HIV Envelope Protein gp41
  • Peptide Fragments
  • Receptors, CCR5
  • Enfuvirtide